HealthMore in Health→
Trial Finds Genetic Clue to Which Children May Benefit From a Targeted Cancer Therapy
Key Takeaways
- Researchers tested a low-dose irinotecan and PARP inhibitor combination.
- Twelve patients benefited across several pediatric tumor types.
- Gene alterations linked to faulty DNA repair were associated with response.
DE
DT Editorial Team··via medicalxpress.com